Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Abstract Background Nimotuzumab (NTZ) is an anti-EGFR monoclonal antibody. However,the effect of targeted drugs combined with induction therapy in locally advanced nasopharyngeal carcinoma remains unclear. The aim of this study is to investigate the safety and efficacy of NTZ combined with cisplatin...

Full description

Bibliographic Details
Main Authors: Ying Lu, Dagui Chen, Jinhui Liang, Jianquan Gao, Zhanxiong Luo, Rensheng Wang, Wenqi Liu, Changjie Huang, Xuejian Ning, Meilian Liu, Haixin Huang
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Cancer
Subjects:
Locally advanced nasopharyngeal carcinoma
EGFR monoclonal antibody
Induction therapy
Curative effect
Adverse reaction
Online Access:https://doi.org/10.1186/s12885-019-6459-6

Internet

https://doi.org/10.1186/s12885-019-6459-6

Similar Items